シンポジウムセッション
第1日 6月10日（月） 16:05～16:25 A会場（中ホール300）
- 1A-S-1605
Integrative Clinical Proteomics and Metabolomics Towards Biomarker Development of Urological cancers
(1Chang Gung University・ 2Chang Gung Memorial Hospital)
oChen, Yi-Ting1・ Chen, Chien-Lun2・ Yu, Jau-Song1
Bladder cancer (BLCA) is a major cancer of the genitourinary system. Although cystoscopy is the standard protocol for diagnosing BLCA clinically, this procedure is invasive and expensive. To develop biomarker for disease management. we established several secretome datasets of representative BLCA cell lines, as well as proteome and metabolome of clinical specimens of urological cancers using quantitative proteomics and chemical isotope labeling LC-MS. The following step has been the identification and quantification of proteins/peptides and metabolites associated with the various types of cancers, renal diseases, and energy-metabolism during disease progression. We have established the standard workflow for targeted and precise quantification of more than two hundred of biomolecules in a LC-MS run using multiple reaction monitoring mass spectrometry (MRM-MS) which are now used for candidate biomarker verification. Several biomarker candidates could potentially be used as non-invasive diagnosis, or tumor-stage/grade discriminators for BLCA management, a possibility that warrants future validation in a larger patient cohort.